Seven out of thirteen refractory rheumatoid arthritis patients with six months of follow-up achieved ACR50 response with AlloNK plus rituximab — a 71% response rate in a population where mean disease duration was nearly 15 years and 81% had already failed two or more distinct biologic or targeted synthetic DMARD classes. That is not a soft signal from an optimistic early cohort. That is a hard number from some of the most treatment-exhausted patients in rheumatology, and it is the evidentiary foundation on which Artiva is now building a Phase 3 registrational trial with FDA alignment secured.
The trial design itself carries clinical weight. Approximately 150 patients randomized 2:1 to AlloNK plus rituximab versus rituximab alone, with ACR50 at six months as the primary endpoint. That comparator arm is not a placebo — rituximab in refractory RA is an active agent — which means Artiva is betting the Phase 3 on demonstrating additive B-cell depletion beyond what rituximab achieves alone. The mechanistic logic is that allogeneic NK cells drive deeper and more durable CD19-positive B-cell clearance than rituximab reaches unassisted, functionally approximating CAR-T activity without the manufacturing constraints or the safety profile that locks CAR-T to academic centers. Zero cases of CRS or ICANS across all autoimmune patients treated to date, and all administrations completed in outpatient community settings — that tolerability picture is what makes a 150-patient community-based Phase 3 operationally plausible rather than aspirational.
The basket data beyond RA adds context that the headline number undersells. Seven Sjögren’s disease patients and four systemic sclerosis patients with six months of follow-up are small denominators, but the absence of relapse or new immunosuppressant initiation across indications points to durability that ACR50 alone cannot capture. If B-cell reconstitution timelines track consistently across diseases, the mechanistic story tightens considerably — and regulators will notice that Artiva is running a single registrational trial rather than staging multiple indication-specific programs sequentially.
The number to track from here is durability of ACR50 response beyond six months in the company-sponsored Phase 2a cohort. If responses hold at twelve months without additional dosing, the treatment paradigm shifts from chronic immunosuppression to episodic intervention — a distinction that reshapes both the clinical protocol and the commercial conversation with payers entirely.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
